-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Initiates Coverage On NewAmsterdam Pharma Co with Buy Rating, Announces Price Target of $44

Benzinga·06/10/2025 14:25:38
Listen to the news
Stifel analyst James Condulis initiates coverage on NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy rating and announces Price Target of $44.